Researchers at Roswell Park Comprehensive Cancer Center identified HSP60 as a new treatment target for neuroendocrine prostate cancer.
This protein helps maintain mitochondrial function, which supports cancer growth and drug resistance. Inhibiting HSP60 disrupts β-catenin signaling, making tumors less aggressive and sensitive to treatments like cisplatin. This discovery offers a promising approach for castrate-resistant cancers that don't respond to traditional therapies, potentially using existing drugs to improve outcomes.
The findings were published in Oncogene.
New prostate cancer diagnosis @ 52
Metastatic prostate cancer due to have chemotherapy 
Prostate cancer